Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling

High tumour mutational burden (TMB-high), identified through comprehensive genomic profiling (CGP), is a biomarker that predicts the efficacy of immune checkpoint inhibitors. CGP testing is recommended for rare cancers with limited effective treatment options. Here, we provide the first report of a...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Hiroo Katsuya, Haruhiko Sano, Haruna Sano, Tatsuya Mihashi, Chiho Nakashima, Keita Kai, Shinya Kimura
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2025-02-01
Reeks:	Frontiers in Immunology
Onderwerpen:	immune checkpoint inhibitor (ICI) tumour mutational burden (TMB) malignant phyllodes tumor of the breast comprehensive genomic profiling (CGP) microsatellite instability
Online toegang:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549452/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!